Fred Alger Management LLC Has $20.29 Million Stock Holdings in Abbott Laboratories $ABT

Fred Alger Management LLC reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 43.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,446 shares of the healthcare product maker’s stock after selling 117,261 shares during the period. Fred Alger Management LLC’s holdings in Abbott Laboratories were worth $20,285,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the 3rd quarter worth $31,000. Anfield Capital Management LLC boosted its stake in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories in the second quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories in the third quarter valued at about $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 1.8%

NYSE:ABT opened at $109.93 on Tuesday. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The company has a market cap of $191.03 billion, a PE ratio of 29.55, a P/E/G ratio of 1.72 and a beta of 0.74. The firm’s 50 day simple moving average is $114.25 and its 200 day simple moving average is $123.65.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Activity

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction on Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ABT shares. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Citigroup lowered their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Finally, Royal Bank Of Canada cut their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.